The increasing worldwide prevalence of diabetes mellitus (DM) means almost 360 million people are suffering from this disease (in 2011) and it is estimated to reach 552 million people by 2030. 1 The latest European Action on Secondary Prevention by Intervention to Reduce Events (EuroASPIRE) study (2013) has revealed that the mean prevalence of DM in European patients with coronary artery disease (CAD) is around 38 %, with Cyprus leading the way with 55 % and Russia coming last with 27 %.
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Cardiovascular Risk
The increasing worldwide prevalence of diabetes mellitus (DM) means almost 360 million people are suffering from this disease (in 2011) and it is estimated to reach 552 million people by 2030. 1 The latest European Action on Secondary Prevention by Intervention to Reduce Events (EuroASPIRE) study (2013) has revealed that the mean prevalence of DM in European patients with coronary artery disease (CAD) is around 38 %, with Cyprus leading the way with 55 % and Russia coming last with 27 %. 2 Morbidity and mortality from cardiovascular disease is 2-5 times higher in patients with DM compared with the general population, and diabetes provides a two-fold increase of risk of other vascular diseases independent of other risk factors. 3 Multiple studies have shown that hyperglycaemia is associated with an increased risk for coronary heart disease as well as atherosclerotic disease. This is true both for diabetic patients and those with impaired glucose tolerance, although the risk varies between 2-4 times in diabetic patients and 1.5 times for patients with impaired glucose tolerance. Whether impaired fasting glucose also carries additional risk is controversial.
Glycaemic control therefore appears to be of utter importance especially since just half of the European patients with CAD screened by EuroASPIRE IV attained a <7.0 % glycated haemoglobin (HbA1 c ) and only 35 % of them scored <6.5 %. 2 Based on the results of several studies, a HbA1 c reduction of ~1 % is associated with 15 % relative risk reduction in non-fatal myocardial infarction but without benefits on stroke or all-cause mortality. 4 A HbA1 c <7.0 % target was shown to reduce microvascular disease but has yet to prove a major benefit on macrovascular risk.
Tight glycaemic control exerts a favourable effect on cardiovascular diseases, which is visible only after many years. However, a combination of glucose control with lipid-lowering medication and antihypertensive medication leads to an improvement in the rate of cardiovascular events. 1 Moreover, although the remaining normoglycaemic population appears to be larger than previously recorded by the EuroASPIRE III trial (33.7 versus 29.5 %), the prevalence of DM has increased from 23.5 % to 26.8 %, not counting the newly diagnosed cases (13.4 %).
This was probably owing to the decrease in the population with impaired fasting glucose and impaired glucose tolerance who have likely developed DM between the two EuroASPIRE trials. 2 Yet, as crucial as glycaemic control is, just half of the European population is aware of their glucose levels, ranging from 96 % in Slovenia to 8 % in
Belgium. 2 This attitude should be changed since successful glucoselowering therapy is most efficient when supported by self-monitoring of blood glucose.
However, macrovascular complications gradually emerge long before the actual diagnosis of DM occurs, due to impaired glucose tolerance characterised by long-standing insulin resistance, compensatory hyperinsulinaemia and varying degrees of elevated plasma glucose, which lead in the end to the onset of DM. This process is identified by the development of an atherosclerotic plaque, which in the presence of enhanced inflammatory content becomes unstable and prone to rupture. Atheroma from patients with DM has more lipid, inflammatory changes and thrombus than a normal subject. Cardiovascular Risk
Assessing cardiovascular risk in patients with DM can be achieved through various methods, one of the most popular being the Systematic Coronary Risk Evaluation (SCORE) risk diagrams. According to these, DM or chronic kidney disease, or very elevated cholesterol or blood pressure places the patient at a high risk (5-10 %) of developing a fatal cardiovascular event in the next ten years (see Figure 1) .
On the other hand, assessing the risk of type 2 DM can be conducted using the Finnish Diabetes Risk Score (FINDRISC) questionnaire, which addresses the risk of developing type 2 DM in the next ten years, by dividing it in low, moderate, high and very high risk.
CAD accounts for over 60 % mortality in people with DM, more than twice the non-diabetic population, while impaired glucose metabolism, comprising of impaired fasting glycaemia and impaired glucose tolerance, is also linked to CAD -since moderately elevated glucose levels below the threshold for DM also represent an increased risk. 7 Moreover, established DM is associated with impaired prognosis after myocardial infarction. 8 The Euro Heart Survey programme carried out a study on diabetes and the heart, trying to assess the prevalence of DM and impaired glucose regulation in adult patients with CAD, and to compare diagnostic and therapeutic tools suitable for these patients. 9 In their 4,961 cohort of people from 110 European countries admitted with CAD, only 29 % with acute CAD and 34 % with stable CAD were normoglycaemic, thereby concluding that it was unusual to have normal glucose tolerance in patients with CAD. 9 The results from the Euro Heart Survey showed that out of the population classified to have impaired glucose tolerance, while 5 % diabetes. 9 However, abnormal glucose tolerance seems to be quite common in the general population, as a study on the Australian population aged 65 discovered similar results, 8 % having undiagnosed diabetes and 25 % impaired glucose metabolism. 10 While this conclusion appears to be true, it also suggests that it is more common in people with CAD and that an oral glucose tolerance test should be performed on a routine basis for such patients, as fasting glycaemia proves to be insufficient. 9 An international expert committee issued a report in 2009 on the role of HbA1 c in diagnosing diabetes and concluded that HbA1 c between 5.7 % and 6.5 % places the patient at high-risk for developing diabetes, while values over 6.5 % signify undiagnosed diabetes.
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A statistic concerning the mortality rate among the diabetic population places cardiovascular disease in the top leading causes of death.
Therefore, ischaemic heart disease is by far the most important cause of death for patients with type 2 DM followed by other heart diseases and stroke, while diabetes itself comes in fourth.
care. 3 Several other hypoglycaemic drugs are commonly employed for diabetes but lack enough data to recommend their use as treatments to reduce cardiovascular events. 18 Acarbose, an alpha-glucosidase inhibitor, reduced the rate of myocardial infarction by 91 % and a composite of cardiovascular events by 49 % in patients with impaired glucose tolerance in the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial. 19 However, cardiovascular risk reduction with acarbose has not been reported in diabetes. Neither incretin mimetics, dipeptidyl peptidase IV (DPP IV) nor sodium-glucose co-transporter 2 (SGLT2) inhibitors have thus far (in clinical trial data) demonstrated cardiovascular event reduction. 18 Statins should be given to all type 2 diabetic patients over the age of 40 years who do not have established cardiovascular disease, but with cardiovascular risk factors (one of which is DM), in order to prevent major cardiovascular events. Trials which reported the outcome of coronary events in diabetic patients showed a 17-36 % reduction in the odds of people receiving statins. 3 A subsequent meta-analysis regarding the use of statins in primary and secondary prevention confirmed that statins offer benefits for people at high-risk of cardiovascular diseases including patients with diabetes. 3 Lowering blood pressure in diabetic patients reduces the risk of micro-and macrovascular complications. Low-dose thiazides/ angiotensin-converting enzyme (ACE) inhibitors are recommended as first-line treatment of hypertension in diabetic patients, and they can be combined. Beta-blockers are not recommended for initial management of hypertension in patients with DM, but can be used if thiazides or ACE inhibitors are contraindicated.
